Site navigation

Navigation

Multiple myeloma - bortezomib

Bortezomib monotherapy for relapsed multiple myeloma

Status:	History
Expected date of issue:	TBC
Process:	STA
Topic area: Cancer

Project team | Schedule | Stakeholders | Project history | Key documents

NICE project team

Executive Lead:	Peter Littlejohns
Technical Lead:	Helen Chung
Communications manager:	Phil Ranson
Project manager:	Natalie Bemrose
Evidence review group:	National Coordinating Centre for Health Technology Assessment Southampton, Southampton Health Technology Assessment Centre (SHTAC)

Top

Provisional schedule

Closing date for invited submissions / evidence submission:	28 February 2006
1st appraisal committee meeting:	04 July 2006
2nd appraisal committee meeting	06 September 2006
3rd appraisal committee meeting:	08 May 2007
4th appraisal committee meeting:	04 July 2007

Top

Consultees and Commentators

Consultees

Commentators (no right of appeal)

Manufacturers / Sponsors

Janssen-Cilag (bortezomib)

Patient / Carer Groups

Cancer BACUP
Myeloma UK
Leukaemia Care Society

Professional Groups

British Society for Haematology
Cancer Network Pharmacist Forum
Cancer Research UK
Royal College of Nursing
RoyalCollegeof Pathologists
RoyalCollegeof Physicians' Medical Oncology Joint Special Committee
UKMyeloma Forum

Others

Department of Health
Welsh Assembly Government

General

British National Formulary
Department of Health, Social Services and Public Safety (Northern Ireland)
National Coordinating Centre for Health Technology Assessment (NCCHTA)
NHS Quality Improvement Scotland

Comparator Manufacturers

Schering-Plough Ltd (interferon alfa-2b)

Evidence Review Groups

None

Associated Guideline Groups

National Collaborating Centre for Cancer

Associated Public Health Groups

None

Research Groups

Instituteof CancerResearch
Leukaemia Research Fund

Top

Project history

Date	Update
5 December 2005	Press statement response 20 July 2005 regarding referral of trastuzumab and bortezomib added.
5 December 2005	List of consultee and commentators added.
5 January 2006	Schedule updated.
22 March 2006	Project team updated.
14 September 2006	Project team updated.
17 October 2006	Project team and stakeholders updated.
19 October 2006	Schedule updated.
27 April 2007	Project team updated
13 July 2007	Schedule updated

Top

Key documents

	Bortezomib monotherapy for relapsed multiple myeloma (final appraisal determination)	30 August 2007
	Multiple myeloma - bortezomib: appraisal consultation	04 June 2007
	Letter sent to consultees and commentators updating them on the status of the appraisal	18 April 2007
	Letter to Department of Health following Appeal Panel decision	18 April 2007
	Letter to consultees and commentators requesting views on unlicensed use	18 April 2007
	Letter to Janssen-Cilag (Ortho Biotech) following Appeal Panel decision requesting additional cost effectiveness evidence	18 April 2007
	Letter to Welsh Assembly Government following Appeal Panel decision	18 April 2007
	Multiple myeloma - bortezomib: Appeal panel decision	29 March 2007
	Appeal by Janssen-Cilag Ltd	08 February 2007
	Joint appeal by the Royal College of Pathologists and the British Society for Haematology	08 February 2007
	Covering letter for joint appeal by Myeloma UK, Cancerbackup and Leukaemia CARE	08 February 2007
	Joint appeal by Myeloma UK, Cancerbackup and Leukaemia CARE	08 February 2007
	Letter to John Redwood referenced in Myeloma UK joint submission	08 February 2007
	Appeal by UK Myeloma Forum	08 February 2007
	Appeal against bortezomib monotherapy for relapsed multiple myeloma	21 December 2006
	Final appraisal determination: Bortezomib monotherapy for relapsed multiple myeloma	20 October 2006
	Appeal announcement: Bortezomib monotherapy for relapsed multiple myeloma	13 December 2006
	Multiple myeloma - bortezomib: Appraisal consultation document	24 July 2006
	Evidence considered	24 July 2006

This page was last updated: 13 July 2007

Site tools